Zhang Yang-Zhou, Gong Hua, Yang Juan, Bu Ji-Pu, Yang Hui-Ling
Institute of Molecular Precision Medicine and Hunan Key Laboratory of Molecular Precision Medicine, Xiangya Hospital, Central South University,Changsha 410008, Hunan Province, China.
Department of Ophthalmology, Xingsheng Hospital, Yiyang 413200, Hunan Province, China.
World J Diabetes. 2024 Aug 15;15(8):1734-1741. doi: 10.4239/wjd.v15.i8.1734.
Non-proliferative diabetic retinopathy (NPDR) poses a significant challenge in diabetes management due to its microvascular changes in the retina. Laser photocoagulation, a conventional therapy, aims to mitigate the risk of progressing to proliferative diabetic retinopathy (PDR).
To compare the efficacy and safety of multi-spot single-spot scanning panretinal laser photocoagulation in NPDR patients.
Forty-nine NPDR patients (86 eyes) treated between September 2020 and July 2022 were included. They were randomly allocated into single-spot ( = 23, 40 eyes) and multi-spot ( = 26, 46 eyes) groups. Treatment outcomes, including best-corrected visual acuity (BCVA), central macular thickness (CMT), and mean threshold sensitivity, were assessed at predetermined intervals over 12 months. Adverse reactions were also recorded.
Energy levels did not significantly differ between groups ( > 0.05), but the multi-spot group exhibited lower energy density ( < 0.05). BCVA and CMT improvements were noted in the multi-spot group at one-month post-treatment ( < 0.05). Adverse reaction incidence was similar between groups ( > 0.05).
While energy intensity and safety were comparable between modalities, multi-spot scanning demonstrated lower energy density and showed superior short-term improvements in BCVA and CMT for NPDR patients, with reduced laser-induced damage.
非增殖性糖尿病视网膜病变（NPDR）因其视网膜微血管变化，在糖尿病管理中构成重大挑战。传统治疗方法激光光凝术旨在降低进展为增殖性糖尿病视网膜病变（PDR）的风险。
比较多点与单点扫描全视网膜激光光凝术在NPDR患者中的疗效和安全性。
纳入2020年9月至2022年7月期间接受治疗的49例NPDR患者（86只眼）。他们被随机分为单点组（n = 23，40只眼）和多点组（n = 26，46只眼）。在12个月内的预定时间间隔评估治疗结果，包括最佳矫正视力（BCVA）、中心黄斑厚度（CMT）和平均阈值敏感度。同时记录不良反应。
两组间能量水平无显著差异（P > 0.05），但多点组能量密度较低（P < 0.05）。多点组在治疗后1个月时BCVA和CMT有所改善（P < 0.05）。两组间不良反应发生率相似（P > 0.05）。
虽然两种方式的能量强度和安全性相当，但多点扫描能量密度较低，且对NPDR患者的BCVA和CMT有更好的短期改善效果，同时减少了激光诱导的损伤。
